Clinical, Biochemical and Molecular Evaluations of Ivermectin Mucoadhesive Nanosuspension Nasal Spray in Reducing Upper Respiratory Symptoms of Mild COVID-19

BACKGROUND: Ivermectin is an FDA-approved broad-spectrum anti-parasitic agent that has been shown to inhibit SARS-CoV-2 replication in vitro. OBJECTIVE: We aimed to assess the therapeutic efficacy of ivermectin mucoadhesive nanosuspension intranasal spray in treatment of patients with mild COVID-19....

Descripción completa

Detalles Bibliográficos
Autores principales: Aref, Zaki F, Bazeed, Shamardan Ezz Eldin S, Hassan, Mohammed H, Hassan, Abeer S, Rashad, Alaa, Hassan, Rehab G, Abdelmaksoud, Aida A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8215847/
https://www.ncbi.nlm.nih.gov/pubmed/34163159
http://dx.doi.org/10.2147/IJN.S313093

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8215847/
https://www.ncbi.nlm.nih.gov/pubmed/34163159
http://dx.doi.org/10.2147/IJN.S313093

Ejemplares similares